|

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

RECRUITINGSponsored by Leiden University Medical Center
Actively Recruiting
SponsorLeiden University Medical Center
Started2023-01-01
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT06932081

Summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Congenital heart defect.
* Age ≥ 18 years.
* Initiated on treatment with an SGLT2i.

Exclusion Criteria:

\- No consent for data collection.

Conditions9

Adult Congenital Heart DiseaseCongenital Heart DiseaseCongenitally Corrected Transposition of the Great ArteriesFontanHeart DiseaseSingle-ventricleSystemic Right VentricleTetralogy of Fallot (TOF)Transposition of the Great Arteries

Locations3 sites

Maryland

1 site
Johns Hopkins University
Baltimore, Maryland, 21205
Ari M. Cedars, MD PhD

Michigan

1 site
Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503
Gruschen R. Veldtman, MBChB FRCP

New York

1 site
Mount Sinai Fuster Heart Hospital
New York, New York, 10029
Ali Zaidi, MD

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.